Open Access by Ann K Kvam
RESEARCH Open Access
Minimal important differences and response shift
in health-related quality of life; a longitudinal
study in patients with multiple myeloma
Ann K Kvam
1,2*, Finn Wisløff
1,2, Peter M Fayers
3,4
Abstract
Background: We previously reported that changes of 6-17 percent in the EORTC QLQ-C30 scores are regarded
important by patients with multiple myeloma and thus may be considered as Minimal Important Differences
(MIDs). However, patients’ internal standard of measurement may have changed over time (response shift, RS). In
the present work, we evaluated whether myeloma patients experience RS and if this could affect the MID-
estimates.
Methods: Between 2006 and 2008, 239 patients with multiple myeloma completed the EORTC QLQ-C30 at
baseline (T1) and after three months (T2). At T2, patients were asked if they had noticed any change in the
domains pain, fatigue, physical function and global quality of life. They were also asked to give a retrospective
judgment of their baseline values on all the four domains.
Results: We found clear evidence of RS in myeloma patients. However, there were differences in both magnitude
and direction between patients who stated that they improved and those who deteriorated. Deteriorating patients
retrospectively reported better health-related quality of life at T1 for the domains pain, fatigue and physical
function. In these patients, MIDs adjusted for RS were observed to increase up to 12 percentage points. In contrast,
for patients stating that they improved, we only found evidence of statistically significant RS in the domain global
quality of life.
Conclusions: MIDs estimated from pre-test/post-test data appeared to be robust against RS in patients reporting
improvement over 3-months. This could indicate that RS has a minimal impact on the results in patients who
respond to treatment, and that RS may not have an important impact on interpretation of changes reported in
clinical trials where an improvement occurs.
Although the effect sizes of the RSs were small, RS in deteriorating patients may have an important impact on the
interpretation of changes reported in clinical trials.
Trial registration: The study is registered at clinicaltrials.gov, identifier NCT00290095.
Background
A challenge in the interpretation of health-related quality
of life (HRQOL) data in clinical research is that HRQOL
is self-reported by the patient, and might be influenced
by psychological phenomena such as adaptation to ill-
ness. Patients who experience changes in health often
accommodate and adapt to these changed conditions.
When measuring changes in HRQOL with a pre-test
(assessment prior to intervention)/post-test (assessment
after intervention) design, as in a Randomized Controlled
Trial (RCT), adaption to increased symptom level or
impaired HRQOL can affect results, a change referred to
as response shift (RS) [1]. Sprangers and Schwartz defined
RS in the field of HRQOL as a change in the meaning of
an individual’s self-reported HRQOL [2]. It can be
divided into 1) Reconceptualization (i.e. a re-definition of
HRQOL), 2) Reprioritization (i.e. a change in the impor-
tance attributed to component domains constituting
HRQOL) and 3) Recalibration (i.e. a change in a patient’s
internal standards of measurements). The most widely * Correspondence: a.k.kvam@medisin.uio.no
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nal standard is the retrospective pre-test design (then-
test) [1,3]. At post-test, patients are retrospectively asked
to provide a renewed judgment of their HRQOL at base-
line (pre-test). The then-test is ideally completed simulta-
neously with or in close proximity to the post-test,
assuming patients rate their HRQOL on both tests using
the same internal standards.
During the last years, several studies have found evi-
dence for the occurrence of RS in HRQOL in cancer
patients -e.g. [4-10]. RS may sometimes be the result of
an adaptive response to a changed health status, and
may then be viewed as a positive phenomenon to
patients. However, the altered meaning of HRQOL over
time poses a challenge to clinicians in the interpretation
of changes in HRQOL. In a study by Visser et al, fatigue
was assessed in 216 cancer patients before and after
treatment with radiotherapy [4]. When the conventional
pre-test was compared to the post-test, no differences in
fatigue were found. This might lead to the conclusion
that radiotherapy does not affect fatigue. However, when
the then-test was used as the measure of fatigue at base-
line, there appeared to be a statistically significant
increase in fatigue after treatment.
The magnitude and importance of the RS phenom-
enon remains unsolved. A meta-analysis by Schwartz et
al suggested that RS may play a significant role in
HRQOL research and that the direction of this shift var-
ies across studies [11]. In a previous report we
attempted to determine the clinical significance of
changes in quality-of-life scores in patients with multiple
myeloma (MM) [12]. MM is an incurable malignant dis-
ease of the bone marrow with an expected median sur-
vival of five years [13]. At diagnosis, myeloma patients
report a pronounced impairment of HRQOL, with
reduced physical functioning, fatigue and pain as the
major problems [14]. Aims of treatment are to control
disease, maximize quality of life and prolong survival.
Hence, HRQOL is an important outcome in clinical
trials. We estimated the Minimal Important Difference
(MID) in patients with MM for the HRQOL instrument,
the EORTC QLQ-C30. MID is defined as “the smallest
difference in score in the domain of interest which
patients perceive as beneficial and which would man-
date, in the absence of troublesome side effects and
excessive cost, a change in the patients’ management”
[15]. Our results suggested that a change in the EORTC
QLQ-C30 score in the range of approximately 6-17 (on
a 0-100 scale) is considered important by patients with
MM. Here, we evaluate whether patients experienced
RS, and if so its magnitude and direction. We also
explore how RS affects the MID-results and whether RS
impacts on the interpretation of HRQOL results in clini-
cal trials.
Methods
Patients
Patients with MM, irrespective of their disease status
(newly diagnosed, plateau phase, relapsed) or treatment,
were enrolled from January 2006 to April 2008. Eligibil-
ity was expected survival greater than three months and
ability to complete a self-report questionnaire in Norwe-
gian. Consecutive patients admitted to 17 hospitals in
the South-Eastern Norway Regional-Health-Authority, a
region representing about 50% of the Norwegian popu-
lation, were recruited. Written informed consent was
obtained from all participants. The Helsinki Declaration
guidelines were followed. The Regional Committee for
Medical Research Ethics, Health region I, Norway,
approved the study.
Questionnaire
HRQOL was measured using the EORTC QLQ-C30, a
cancer-specific questionnaire with 30 items [16]. The
questionnaire is composed of five functional scales,
three symptom scales, a global health/quality of life
scale, and six single items. All scores were calculated
and transformed to a 0-100 scale according to EORTC
methods [17]. For the functional scales and global health
status, higher scores represent a higher level of function-
ing. In the symptom scales and single items, higher
scores represent more symptoms or difficulties. The
questionnaire is reliable and valid for MM patients [18].
Interview and Then-test approach
Patients completed the EORTC QLQ-C30 at inclusion
(T1) and after three months (± 2 weeks window) (T2).
At T2, a structured interview was performed and the
patients were asked: “Compared with the last time you
filled in the questionnaire (T1, date mentioned to the
patients), has your quality-of-life improved, stayed the
same or deteriorated?” The response choices ranged on
a seven-point scale from 1 = much better to 7 = much
worse. This global rating of change (GRC) question was
asked for the four domains physical functioning, fatigue,
pain and global quality of life. Because of small sample
sizes in some of the GRC categories, we pooled the data
into three categories (improved, unchanged, deterio-
rated) to yield sufficient numbers of cases in each cate-
gory. “Improved” included much better, moderately
better and a little better and “deteriorated” included a
little worse, moderately worse and much worse for the
four domains. MIDs for improvement and deterioration
were defined as the mean score changes in these
domains for patients declaring improvement or dete-
rioration. During the article we would use improved as
shorthand for patients “who reported themselves as
improved”, and similarly for deteriorated and unchanged
patients.
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provide a renewed judgment of their baseline ratings of
the EORTC QLQ-C30 for the four domains (Then-test).
The questions were asked in past tense for each of the
12 items included in these domains. We emphasized
that the purpose of the then-test was not to recall their
previous answers but to provide a renewed judgment of
their HRQOL at baseline.
The mean difference between the pre-test and then-
test scores was used to provide an estimate of the direc-
tion and magnitude of the RS effect. Observed changes
were calculated by the difference between the mean
post-test and pre-test scores while adjusted changes
were measured as the difference between mean post-test
and then-test scores.
Statistical methods
Wilcoxon tests for pair differences were used to calcu-
late the significance of differences between pre-test,
post-test and then-test. We divided the patients into
groups according to whether they thought they were
improved, unchanged or deteriorated for the four
domains.
To examine the magnitude of recalibration RS, effect
sizes (ES) were calculated by dividing the mean score
changes by the standard deviation at baseline (T1). We
used Cohen’s generally accepted criteria for interpreting
the magnitude of an ES: > 0.20 is a small change, > 0.50
a moderate change, and > 0.80 a large change [19].
T h eG R Cr e s u l t sa n dt h eo b s e r v e da n da d j u s t e d
changes all appeared approximately to reflect underlying
normal distributions. Analysis of variance (ANOVA)
was performed and F-statistics values were calculated to
see which approach (a seven-point GRC scale, observed
changes or adjusted changes) was most efficient at
detecting changes in phases of the disease (newly diag-
nosed, relapse/progression or stable disease). Newly
diagnosed patients were expected to improve, relapsed
patients to deteriorate and patients with a stable disease
to stay unchanged. The relative efficiency of a test is
measured by the ratio of the F-statistics values [20]
Missing data
I fa n yi t e mw a sm i s s i n gi nt h ef i r s tq u e s t i o n n a i r e( T 1 ) ,
we accepted the data as missing. For the second ques-
tionnaire (T2), the forms were checked and if any item
was missing the patients were asked to fill it in before
the interview. Still, if any of the constituent items in a
scale were missing, the scale score for that patient was
excluded from the statistical analyses.
Sample size calculation
The study primarily aimed to estimate the MID and
sample size calculation was based on being able to
d e t e c taM I Do f0 . 5 0×S D ,y i e l d i n gas a m p l es i z eo f
260 patients. The response shift evaluation is descriptive
and so the impact of sample size is indicated by confi-
dence intervals around the estimates.
The statistical analysis was performed using The
Statistical Package for the Social Sciences (SPSS),
version 16 (SPSS Inc., Chicago, IL, USA).
Results
Study sample
260 patients were recruited, and 239 (92%) who filled in
both questionnaires were interviewed. Of the 21 patients
lost to follow up, seven had died and nine were too ill
to complete the questionnaire at T2. For the remaining
five cases, the reason for lack of follow-up was adminis-
trative problems. Table 1 shows patients’ characteristics.
Fifty-seven percent of the patients completed the post-
test and the then-test within the same or next day while
99% completed them within a week (range 0-22 days).
At baseline, 0.6% of the items were missing from the
EORTC QLQ-C30 questionnaires, which decreased to
0.3% at follow-up. Missing items appeared randomly
distributed across domains.
EORTC QLQ-C30 mean scores
Overall, for patients who improved, the EORTC QLQ-
C30 at post-test showed statistically significant (p <
0.01) better scores (less symptoms and higher func-
tioning) than at pre-test and then-test (Table 2). For
patients who deteriorated, the EORTC QLQ-C30 at
Table 1 Patient characteristics
Multiple myeloma
patients
N = 239
Age (year)
Median (range) 66 (36-89)
Sex, no. (%)
Male 128 (54)
Female 111 (46)
Phase of disease, no. (%)
Newly diagnosed 87 (36)
Stable disease 80 (34)
Relapse/progression 69 (29)
Multiple myeloma treatment during the
study, no (%)
No treatment 86 (36)
MP +/- Thalidomide 55 (23)
ASCT, newly diagnosed 33 (14)
ASCT, relapse 8 (3)
Velcade 7 (3)
Thalidomide 32 (13)
Other 15 (6)
Unknown 3 (1)
MP: Melphalan and Prednisone
ASCT: Autologous stem cell transplantation
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symptoms and lower functioning) than at pre-test and
then-test (p = 0.01). There were no significant
changes in the EORTC QLQ-C30 score from pre-test
to post-test for the unchanged patients. However, for
pain and fatigue, patients reporting no change had
statistically significant more symptoms at post-test
than at then-test (p < 0.01).
Magnitude and direction of RS
Table 3 summarizes the magnitude and direction of RS
(pre-test - then-test scores). Overall, there were differ-
ences in both the magnitude and direction of RS
between patients who improved and those who deterio-
rated. Patients improving from T1 to T2 retrospectively
underestimated their baseline values on all the four
dimensions. However, a statistically significant score dif-
ference (p < 0.01) emerged only for the global quality of
life dimension. In contrast, among patients who deterio-
rated, the participants retrospectively overestimated
their baseline values on the four dimensions. Thus,
there was a statistically significant RS for the domains
pain, fatigue and physical function (p < 0.01). An illus-
tration of the RS-effect for MM patients who deterio-
rated in fatigue is presented in Fig. 1. In the unchanged
group, there was a statistically significant RS for the
domains pain and fatigue (p < 0.01). In these domains,
the unchanged patients retrospectively overestimated
their baseline values.
ESs were largest for those who deteriorated in the
domains fatigue, pain and physical function (ESs were
0.49, 0.35 and 0.33, respectively, Table 3). Using Cohen’s
criteria, all of these ESs could be considered small.
There were trivial ESs for the domains fatigue, pain and
physical function for patients who improved.
Effect on MID estimates
Table 4 shows the observed (post-test - pre-test) and
adjusted (post-test - then-test) mean score changes in
the EORTC QLQ-C30 for the four domains. The
observed changes are defined as MIDs because patients
regard these changes as a definite improvement or dete-
rioration. MIDs (absolute values) for patients rating
themselves as improved ranged from 6.2 (physical func-
tion) to 14.7 (pain). Patients reporting deterioration had
MIDs (absolute values) in the range of 8.6 (fatigue) to
17.3 (pain). However, there was considerable variation
in the observed scores, as shown by the wide confidence
intervals. By using the adjusted, mean changes as MIDs,
the EORTC QLQ-C30 scores varied from 9.3 to 17.5 for
improved patients. Patients who deteriorated had
adjusted mean change scores in the range of 12.2 to 27.
Efficiency in detecting changes
Phase of disease was classified as newly diagnosed, stable
or relapse/progression. Impact of phase of disease on
GRC, observed and adjusted mean scores was explored
using F-statistics values from ANOVA. There were
Table 2 EORTC QLQ-C30 scores for the pre-, post- and then-test
n Pre-test (T1),
mean (SD)
p
a Post-test (T2),
mean (SD)
p
b Then-test,
mean (SD)
Pain*
improved 58 52.6 (32.7) < 0.01 37.9 (27.5) < 0.01 55.5 (24.5)
unchanged 126 28.7 (27.8) 0.29 27.6 (28.0) < 0.01 22.5 (26.1)
deteriorated 50 46.0 (27.7) < 0.01 63.3 (28.6) < 0.01 36.3 (31.0)
Fatigue*
improved 56 51.0 (22.9) < 0.01 37.5 (21.4) < 0.01 51.4 (23.3)
unchanged 119 40.4 (24.6) 0.17 38.7 (26.1) < 0.01 34.2 (25.4)
deteriorated 58 56.3 (25.3) 0.01 64.0 (23.7) < 0.01 43.5 (25.3)
Physical function
†
improved 73 59.9 (22.3) < 0.01 66.3 (20.4) < 0.01 57.5 (24.2)
unchanged 96 69.7 (21.9) 0.77 70.4 (21.5) 0.15 71.7 (22.7)
deteriorated 58 60.8 (22.6) < 0.01 48.1 (21.2) < 0.01 68.3 (21.9)
Quality of life
†
improved 79 59.0 (26.1) < 0.01 66.6 (21.0) < 0.01 51.9 (19.5)
unchanged 110 64.2 (22.1) 0.69 64.5 (21.5) 0.44 63.2 (20.1)
deteriorated 49 48.6 (20.9) < 0.01 36.6 (20.2) < 0.01 48.8 (16.0)
*For the symptom scales pain and fatigue, higher scores represent more symptoms or difficulties
† For the physical function and global quality of life scales, higher scores mean better functioning
SD: Standard deviation
p
a -values denote differences between scale-means at T1 and T2
p
b -values denote differences between scale-means at T2 and then-test
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with the largest F-statistics value for GRC, closely fol-
lowed by adjusted changes (Table 5). For pain, fatigue
and physical function the GRC and adjusted changes
have a relative efficiency (ratio between F statistics) of
approximately three compared to the observed changes,
and for global quality of life the relative efficiency is
two.
Discussion
T h er e s u l t so ft h ep r e s e n ts t u d yi n d i c a t et h a tR Se x i s t s
in MM patients, mainly in those who deteriorated over
the 3-month observation period. We found that patients
who deteriorated in the domains pain, fatigue and
physical function, retrospectively minimized their trou-
bles at baseline. These changes in internalized standards
could be a desirable adaptation mechanism to patients
with cancer to maintain equilibrium in HRQOL in the
face of loss.
Our findings are generally consistent with those of
previous studies among other categories of cancer
patients with deteriorating health conditions [4,5,21].
Jansen et al assessed RS in 46 patients with breast-can-
cer undergoing radiotherapy. They found that patients,
who had deteriorated, retrospectively reported fewer
symptoms at baseline. They concluded that RS mea-
sured by the then-test was stronger for deterioration in
HRQOL than for improvement in HRQOL.
For patients who improved, there was no statistically
significant evidence of RS except for the domain global
quality of life. In RCTs in newly diagnosed patients with
MM or cancer in general, patients are usually followed
from the start of treatment and the majority of patients
are expected to improve [22,23]. Thus, the RS phenom-
enon may arguably be disregarded in the interpretation
of the HRQOL results from such trials. Our results are
in contrast to findings in studies regarding patients with
non-fatal disorders, where improved patients retrospec-
tively have reported significantly higher disability
[24,25]. Razmjou et al discussed this issue in a study of
patients with total knee arthroplasty and concluded that
“it appears that patients who wish to maintain a stable
HRQOL would consciously or unconsciously magnify
their treatment effect by endorsing a higher disability
level retrospectively” [25].
Table 3 Magnitude and direction of response shift for the entire sample
EORTC QLQ-C30 domain N n Response shift 95% CI for response shift p-value ES
Pain 235 4.8 < 0.01 0.16
improved 58 -2.9 -11, 5 0.49 -0.09
unchanged 127 6.4 3, 10 < 0.01 0.23
deteriorated 50 9.7 3, 17 < 0.01 0.35
Fatigue 236 6.2 < 0.01 0.25
improved 56 -0.4 -6, 5 0.82 -0.02
unchanged 121 6.2 3, 9 < 0.01 0.25
deteriorated 59 12.4 7, 18 < 0.01 0.49
Physical function 230 -1.5 0.10 -0.07
improved 74 2.9 0, 6 0.09 0.13
unchanged 98 -1.4 -4, 1 0.22 -0.06
deteriorated 58 -7.4 -12, -3 < 0.01 -0.33
Quality of life 238 2.7 < 0.01 0.11
improved 79 7.1 3, 12 < 0.01 0.27
unchanged 110 0.8 -2, 4 0.55 0.04
deteriorated 49 -0.2 -5, 4 0.86 -0.01
CI: Confidence interval
ES: Effect size (mean score change/SDpretest)
Response shift: Pre-test - Then-test
Figure 1 Observed and adjusted scores of the EORTC QLQ-C30
for MM patients deteriorated in fatigue (n = 58). The patients
evaluated their fatigue in retrospect as better (less fatigue) than
they did at T1. The difference between the pre-test and then-test
score is the response shift effect.
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were unchanged from T1 to T2, mainly for the domains
pain and fatigue. On the average, these patients retro-
spectively underestimated their symptoms. A meta-ana-
lysis by Hagedoorn et al [7] concluded that RS is a
common and significant phenomenon in HRQOL mea-
surement, and that in cancer studies, patients with a
declining HRQOL may report no decrease in their
HRQOL due to positive adaptation. This could be an
explanation for the findings for the unchanged group in
our study.
ESs can be calculated to evaluate the importance of
the observed RS. In our study, we found that the ESs of
the RS were small according to Cohen’s criteria with the
largest ES detected for fatigue. Fatigue has been identi-
fied by patients with cancer as a major obstacle to nor-
mal functioning and a good quality of life [26]. Previous
studies have suggested that fatigue is a symptom that is
especially RS prone [4,21].
It is important to know the clinical significance of
changes in HRQOL scores for the interpretation of the
results from clinical trials. We have previously reported
that a difference of 6-17 points (scale range 0-100) in
the EORTC QLQ-C30 score represents a clinically
meaningful change in patients with MM. In the present
study, we found that by controlling for RS in patients
who improved, the same interval for MIDs could be
used. However, if we adjust for RS in patients who dete-
riorated, larger MIDs (12-27 points) are obtained. The
question is still: does adjusting for RS provides more
reliable estimates of MIDs?
The F-statistics values from ANOVA indicates that
the GRC is the most effective method for detecting dif-
ferences in phase of disease, with RS adjusted changes
Table 4 Minimal important differences calculated by observed- and adjusted mean score changes
Observed changes
†
(Post-test - Pre-test)
Adjusted changes
(Post-test - Then-test)
N Mean change SD 95% CI Mean change SD 95% CI
Pain
a 234* 30.8*
improved 58 -14.7 35.9 (-24,-5) -17.5 27.1 (-25,-10)
unchanged 126 -1.7 20.9 (-5,2) 4.9 19.5 (2,8)
deteriorated 50 +17.3 23.1 (11,24) +27.0 29.9 (19,35)
Fatigue
a 233* 25.3*
improved 56 -13.5 24.7 (-20,-7) -13.9 26.3 (-21,-7)
unchanged 119 -2.0 17.3 (-5,1) 4.6 16.5 (2,8)
deteriorated 58 +8.6 23.4 (3,15) +20.5 22.3 (15,26)
Physical Function
b 227* 22.6*
improved 73 +6.2 15.3 (3,10) +9.3 16.1 (6, 13)
unchanged 96 -0.1 12.6 (-3,3) -1.6 10.4 (4,0)
deteriorated 58 -12.8 19.2 (-18,-8) -20.1 18.9 (-15,-25)
Quality of Life
b 238* 23.9*
improved 79 +7.6 23.7 (2,13) +14.7 19.8 (10,19)
unchanged 110 0.4 19.1 (-3,4) 1.3 15.7 (-2,4)
deteriorated 49 -12.1 21.2 (-18,-6) -12.2 14.7 (-8,-12)
a: Positive scores mean worse symptoms
b: Positive scores mean better functioning
†: Observed changes are defined as minimal important differences because these are the changes that patients regard as a definite improvement or
deterioration)
*: Total sample (improved, no change and deteriorated)
CI: Confidence Interval
Table 5 Results of the F-statistics from ANOVA for the domains pain, fatigue, physical function and global quality of
life, by phase of disease
Pain Fatigue Physical Function Global quality of life
GRC 12.7* 8.0* 10.0* 11.9*
Observed changes (Post-test - Pre-test) 3.6* 1.6
† 5.6* 6.0*
Adjusted changes (Post-test - Then-test) 10.7* 4.7* 17.0* 9.9*
GRC: global rating of change
*p < 0.05
†p=0 . 2
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actual clinical practice, in which health-care providers
usually rely on patients’ judgment if they are better, the
same or worse. However, the question remains, which is
the most meaningful and least biased outcome? The
most sensitive outcome could be the most biased. If
patients are aware that the phase of their disease is dete-
riorating, they may be more prone to assuming that
their HRQOL must as a consequence be similarly
declining, resulting in biased reports of GRC and possi-
bly RS adjusted changes.
A possible explanation for the discrepancy between
the pre-test and then-test assessment is the potential for
recall bias. In HRQOL research, recall bias refers to
memory distortion; that is if patients incorrectly recall
their health condition at T1 [27,28]. However, in a study
by Visser et al comparing different approaches to detect
RS, recall bias did not invalidate then-test result [29]. A
factor such as the length of period between measure-
ments may affect the influence of recall bias. Like Visser
and others [9,29], we used a relatively short interval
between assessments (3 months). If we had chosen a
shorter interval between pre-test and then-test, the
patients could have remembered what they actually
answered on the pre-test. A longer period between the
initial measurement and the retrospective then-test
w o u l dp o s eac o n s i d e r a b l ec h a l l e n g et om e m o r y .T h e
choice of 3 months in the present study was a compro-
mise between these considerations. Another possible
explanation for the observed results could be the “impli-
cit theory of change”. This theory suggests that patients
begin with their presumed present state (post-test) and
work backwards to their pre-test state (pre-test), and
not on their perception of their health at a specific time
point [27]. A consequence could be that patients view
the decline in their HRQOL as bigger than it actually is
because they believe their disease is progressing and
that consequently their HRQOL must be deteriorating.
A l t h o u g hR Sc o u l db eac h a l l e n g ef o rt h em e a s u r e -
ment and interpretation of self-reported HRQOL, adap-
tion to illness could serve as a form of psychological
buffer that helps reduce the stressful impact of a dete-
riorating health status. For most patients, living after
being diagnosed with cancer is not the same as before.
An important part of every cancer treatment is helping
patients to adapt to their illness. Thus, the positive
adaption we found in our study in patients saying that
they deteriorated is actually a desired effect for the
patients.
We chose to study MM patients because we antici-
pated large differences in HRQOL score between those
who improved or deteriorated. A comparison with the
results obtained with the EORTC QLQ-C30 in patients
with other haematological diseases [30] and in solitaire
cancers [31,32] indicates that patients’ HRQOL is lower
in MM than in several other malignant diseases.
The evaluation of external validity is important to
enhance the transfer of results into the clinical routine.
T h es t r e n g t ho fo u rs t u d yi st h a tw ei n c l u d e da n
almost representative sample of patients with MM
within the South-Eastern Norway, although the median
age was somewhat lower (66 years) than in a newly
published population based study from Sweden (72
years) [33]. However, the mean EORTC QLQ-C30
scores for the whole sample in our study is comparable
to a nationally representative study among MM
patients in Denmark [30]. Given the representativeness
of the patients included, we can expect the results to
be relevant to other MM patients. We would also
expect these findings to apply to other cancers or
other illnesses, and we encourage confirmatory studies
to investigate this.
Conclusions
In our study, MIDs estimated from pre-test/post-test
data appeared to be robust against RS in patients who
improved over 3-months. This could indicate that RS
h a sam i n i m a li m p a c to nt h er e s u l t si np a t i e n t sw h o
respond to treatment, and that RS may not have an
important impact on interpretation of changes reported
in clinical trials where an improvement occurs.
Although the ESs of the RSs were small, RS in deterio-
rated patients may augment MID estimates with up to
12 points and may have an important impact on the
interpretation of changes reported in clinical trials.
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